ConvaTec Group PLC (CNVVF)
2.995
0.00 (0.00%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.127B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 5.86% |
| Valuation | |
| PE Ratio | 40.47 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.798 |
| Price to Book Value | 3.702 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0186 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8045 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 38.25% |
Profile
| Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue. |
| URL | https://www.convatecgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Mar. 06, 2025 (est.) |
| Last Earnings Release | Jul. 30, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 22, 2024 |
Ratings
Profile
| Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue. |
| URL | https://www.convatecgroup.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Mar. 06, 2025 (est.) |
| Last Earnings Release | Jul. 30, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 22, 2024 |